NCT00835484View on ClinicalTrials.gov

Cefdinir Capsules 300 mg, Fasting

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

July 31, 2005

Study Completion Date

July 31, 2005

Conditions
Healthy
Interventions
DRUG

Cefdinir Capsules 300 mg

1 x 300 mg, single-dose fasting

DRUG

OMNICEF® 300 mg

1 x 300 mg, single-dose fasting

Trial Locations (2)

56721

PRACS Institute, Ltd., East Grand Forks

58104

PRACS Institute, Ltd., Fargo

All Listed Sponsors
lead

Teva Pharmaceuticals USA

INDUSTRY

NCT00835484 - Cefdinir Capsules 300 mg, Fasting | Biotech Hunter | Biotech Hunter